NITROMIST (nitroglycerin) by Pfizer is (no) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic gmp) in smooth muscle and other tissues. First approved in 2006.
Drug data last refreshed 9h ago
NITROMIST is a sublingual metered aerosol formulation of nitroglycerin approved in 2006 for coronary artery disease and heart failure. It works by releasing nitric oxide, which activates guanylate cyclase to increase cyclic GMP in smooth muscle, leading to vasodilation and reduced cardiac workload. The aerosol delivery provides rapid symptom relief for acute anginal episodes.
Product approaching loss of exclusivity signals transition from growth team investment to margin-defense and lifecycle extension strategies; expect smaller, more specialized commercial teams.
(NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Safety of Nitroglycerin for Field Treatment of STEMI
Treatment of Suspected Cholelithiasis With Nitroglycerin
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Worked on NITROMIST at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNITROMIST careers are concentrated in commercial, market access, and managed care roles focused on defending share against newer competitors and generic erosion. Growth opportunities are limited; roles are defensive, emphasizing payer education, formulary placement, and patient loyalty programs rather than new market development. This is ideal for professionals seeking stable, execution-focused roles in a mature therapeutic area rather than growth-stage challenges.